STATE OF IOWA DEPARTMENT OF
Health AND Human
SERVICES

# GENETIC TESTING
# CODES REQUIRING PRIOR AUTHORIZATION

| Code | Description | Effective Date |
|---|---|---|
| **81162** | Gene Analysis (breast cancer 1 and 2) full sequence, analysis and full duplication/deletion analysis | 1/1/2023 |
| **81163** | Gene analysis (breast cancer 1 and 2) of full sequence | 1/1/2019 |
| **81164** | Gene analysis (breast cancer 1 and 2) for duplication or deletion variants | 3/18/2020 |
| **81165** | Gene analysis (breast cancer 1) of full sequence | 1/1/2023 |
| **81166** | Gene analysis (breast cancer 1) for duplication or deletion variants | 1/1/2023 |
| **81167** | Gene analysis (breast cancer 2) for duplication or deletion variants | 1/1/2023 |
| **81170** | Gene analysis (acquired imatinib tyrosine kinase inhibitor resistance) variants in the kinase domain | 5/1/2022 |
| **81171** | Gene analysis (fragile X mental retardation 2) for abnormal alleles | 3/18/2020 |
| **81172** | Gene analysis (fragile X mental retardation 2) for characterization of alleles | 1/1/2023 |
| **81173** | Gene analysis (androgen receptor) of full sequence | 1/1/2023 |
| **81174** | Gene analysis (androgen receptor) for known familial variant | 10/1/2019 |
| **81177** | Gene analysis (atropin 1) for abnormal alleles | 3/18/2020 |
| **81178** | Gene analysis (ataxin 1) for abnormal alleles | 3/18/2020 |
| **81179** | Gene analysis (ataxin 2) for abnormal alleles | 3/18/2020 |
| **81180** | Gene analysis (ataxin 3) for abnormal alleles | 1/1/2023 |
| **81181** | Gene analysis (ataxin 7) for abnormal alleles | 3/18/2020 |
| **81182** | Gene analysis (ataxin 8 opposite strand [non-protein coding]) for abnormal alleles | 1/1/2023 |
| **81183** | Gene analysis (ataxin 10) for abnormal alleles | 1/1/2023 |
| **81184** | Gene analysis (calcium voltage-gated channel subunit alpha1 A) for abnormal alleles | 3/18/2020 |
| **81185** | Gene analysis (calcium voltage-gated channel subunit alpha1 A) of full sequence | 10/1/2019 |
| **81186** | Gene analysis (calcium voltage-gated channel subunit alpha1 A) for known familial variant | 3/18/2020 |
| **81187** | Gene analysis (CCH-type zinc finger nucleic acid binding protein) for abnormal alleles | 3/18/2020 |
| **81188** | Gene analysis (cystatin B) for abnormal alleles | 3/18/2020 |
| **81189** | Gene analysis (cystatin B) of full sequence | 1/1/2019 |
| **81190** | Gene analysis (cystatin B) for known familial variants | 3/18/2020 |
| **81201** | Gene analysis, APC; full gene sequence | 1/1/2013 |

STATE OF IOWA DEPARTMENT OF
Health AND Human
SERVICES

| Code | Description | Effective Date |
|---|---|---|
| **81202** | Gene analysis, APC; known familial variants | 1/1/2013 |
| **81203** | Gene analysis, APC; duplication/deletion variants | 1/1/2023 |
| **81204** | Gene analysis (androgen receptor) for characterization of alleles | 1/1/2019 |
| **81206** | BCR/ABL1 translocation analysis; major breakpoint, qualitative or quantitative | 5/1/2022 |
| **81207** | BCR/ABL1 translocation analysis; minor breakpoint, qualitative or quantitative | 5/1/2022 |
| **81208** | BCR/ABL1 translocation analysis; other breakpoint, qualitative or quantitative | 5/1/2022 |
| **81210** | Gene analysis (B-Raf proto-oncogene, serine/threonine kinase) V600 variant(s) | 5/1/2022 |
| **81212** | BRCA1, BRCA2 gene analysis; variants | 1/1/2023 |
| **81215** | BRCA1 gene analysis; known familial variants | 1/1/2023 |
| **81216** | BRCA2 gene analysis; full sequence analysis | 9/1/2018 |
| **81217** | BRCA2 gene analysis; known familial variants | 9/1/2018 |
| **81228** | Cytogenomic constitutional microarray analysis; interrogation of genomic regions for copy number variants | 11/1/2014 |
| **81229** | Cytogenomic constitutional microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism variants for chromosomal abnormalities | 11/1/2014 |
| **81233** | Gene analysis (Bruton's tyrosine kinase) for common variants | 3/18/2020 |
| **81234** | Gene analysis (DM1 protein kinase) for abnormal alleles | 1/1/2019 |
| **81235** | Gene analysis, EGFR; common variants | 3/18/2020 |
| **81236** | Gene analysis (enhancer of zeste 2 polycomb repressive complex 2 subunit) of full sequence | 1/1/2019 |
| **81237** | Gene analysis (enhancer of zeste 2 polycomb repressive complex 2 subunit) for common variants | 1/1/2019 |
| **81239** | Gene analysis (DM1 protein kinase) for characterization of alleles | 3/18/2020 |
| **81243** | FMR1 gene analysis; evaluation to detect abnormal alleles | 2/1/2015 |
| **81244** | FMR1 gene analysis; characterization of alleles | 2/1/2015 |
| **81252** | Gene analysis, GJB2; full gene sequence | 1/1/2013 |
| **81253** | Gene analysis, GJB2; known familial variants | 1/1/2023 |
| **81254** | Gene analysis, GJB2; common variants | 1/1/2023 |
| **81256** | HFE gene analysis, common variants | 6/1/2015 |
| **81271** | Gene analysis (Huntingtin) for abnormal alleles | 3/18/2020 |
| **81274** | Gene analysis (Huntingtin) for characterization of alleles | 1/1/2023 |

STATE OF IOWA DEPARTMENT OF
Health AND Human
SERVICES

| Code | Description | Effective Date |
|---|---|---|
| **81275** | KRAS gene analysis; variants in exon 2 | 5/1/2022 |
| **81276** | KRAS gene analysis; additional variant(s) | 5/1/2022 |
| **81284** | Gene analysis (frataxin) for abnormal alleles | 1/1/2019 |
| **81285** | Gene analysis (frataxin) for characterization of alleles | 1/1/2023 |
| **81286** | Gene analysis (frataxin) of full sequence | 1/1/2019 |
| **81288** | MLH1(Lynch syndrome) gene analysis; promoter methylation analysis | 6/1/2022 |
| **81289** | Gene analysis (frataxin) for known familial variants | 1/1/2019 |
| **81292** | MLH1 (Lynch syndrome) gene analysis; full sequence analysis | 1/1/2023 |
| **81293** | MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants | 8/1/2022 |
| **81294** | MLH1 (Lynch syndrome) gene analysis; duplication/deletion variants | 6/1/2022 |
| **81295** | MSH2 (Lynch syndrome) gene analysis; full sequence analysis | 1/1/2023 |
| **81296** | MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants | 8/1/2022 |
| **81297** | MSH2 (Lynch syndrome) gene analysis; duplication/deletion variants | 6/1/2022 |
| **81298** | MSH6 (Lynch syndrome) gene analysis; full sequence analysis | 5/1/2022 |
| **81299** | MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants | 1/1/2023 |
| **81300** | MSH6 (Lynch syndrome) gene analysis; duplication/deletion variants | 1/1/2023 |
| **81301** | Microsatellite instability analysis of markers for mismatch repair deficiency, includes comparison of neoplastic and normal tissue, if performed | 12/1/2018 |
| **81305** | Gene analysis (myeloid differentiation primary response 88) for p.Leu265Pro variant | 3/18/2020 |
| **81306** | Gene analysis (nudix hydrolase 15) for common variants | 10/1/2019 |
| **81307** | Gene analysis (partner and localizer of BRCA2) full sequence analysis | 7/1/2020 |
| **81308** | Gene analysis (partner and localizer of BRCA2) for detection of known familial variant | 7/1/2020 |
| **81309** | Gene analysis (partner and localizer of BRCA2) targeted sequence analysis | 1/1/2023 |
| **81311** | NRAS, gene analysis, variants in exon 2 and exon 3 | 5/1/2022 |
| **81312** | Gene analysis (poly[A] binding protein nuclear 1) for abnormal alleles | 1/1/2019 |
| **81317** | PMS2 (Lynch syndrome) gene analysis; full sequence analysis | 5/1/2022 |
| **81318** | PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants | 8/1/2022 |

STATE OF IOWA DEPARTMENT OF
Health AND Human
SERVICES

| Code | Description | Effective Date |
|---|---|---|
| **81319** | PMS2 (Lynch syndrome) gene analysis; duplication/deletion variants | 6/1/2022 |
| **81320** | Gene analysis (phospholipase C gamma 2) for common variants | 3/18/2020 |
| **81321** | PTEN gene analysis; full sequence analysis | 1/1/2013 |
| **81322** | PTEN gene analysis; known familial variant | 1/1/2023 |
| **81323** | PTEN gene analysis; duplication/deletion variant | 1/1/2023 |
| **81324** | PMP22 gene analysis; duplication/deletion analysis | 1/1/2013 |
| **81325** | PMP22 gene analysis; full sequence analysis | 3/18/2020 |
| **81326** | PMP22 gene analysis; known familial variant | 1/1/2023 |
| **81331** | SNRPN/UBE3A, methylation analysis | 12/1/2018 |
| **81333** | Gene analysis (transforming growth factor beta-induced) for common variants | 1/1/2019 |
| **81336** | Gene analysis (survival of motor neuron 1, telomeric) of full sequence | 1/1/2023 |
| **81337** | Gene analysis (survival of motor neuron 1, telomeric) for known familial sequence variants | 3/18/2020 |
| **81343** | Gene analysis (protein phosphatase 2 regulatory subunit Bbeta) for abnormal alleles | 3/18/2020 |
| **81344** | Gene analysis (TATA box binding protein) for abnormal alleles | 3/18/2020 |
| **81345** | Gene analysis (telomerase reverse transcriptase) targeted sequence analysis | 1/1/2019 |
| **81351** | Gene analysis (tumor protein 53) full sequence analysis | 1/1/2021 |
| **81352** | Gene analysis (tumor protein 53) targeted sequence analysis | 1/1/2021 |
| **81353** | Gene analysis (tumor protein 53) targeted sequence analysis for detection of known familial variant | 1/1/2021 |
| **81373** | HLA Class I typing, low resolution; one locus, each | 12/1/2018 |
| **81381** | HLA Class I typing, high resolution; one allele or allele group, each | 1/1/2023 |
| **81401** | Molecular Pathology Procedure Level 2 | 5/1/2022 |
| **81402** | Molecular Pathology Procedure Level 3 | 5/1/2022 |
| **81403** | Molecular Pathology Procedure Level 4 | 6/1/2022 |
| **81404** | Molecular pathology procedure, Level 5 | 3/18/2020 |
| **81405** | Molecular pathology procedure, Level 6 | 9/1/2018 |
| **81406** | Molecular pathology procedure, Level 7 | 5/1/2022 |
| **81407** | Molecular pathology procedure, Level 8 | 9/1/2018 |
| **81408** | Molecular pathology procedure, Level 9 | 9/1/2018 |

STATE OF IOWA DEPARTMENT OF
Health AND Human
SERVICES

| Code | Description | Effective Date |
|---|---|---|
| **81415** | Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis | 1/1/2023 |
| **81416** | Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents, siblings) | 1/1/2023 |
| **81417** | Exome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence | 12/1/2021 |
| **81420** | Fetal chromosomal aneuploidy genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21 | 6/1/2023 |
| **81433** | Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11 | 6/1/2023 |
| **81435** | Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis); genomic sequence analysis panel, must include sequencing of at least 10 genes, including APC, BMPR1A, CDH1, MLH1, MSH2, MSH6, MUTYH, PTEN, SMAD4, and STK11 | 6/1/2023 |
| **81436** | Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis); duplication/deletion analysis panel, must include analysis of at least 5 genes, including MLH1, MSH2, EPCAM, SMAD4, and STK11 | 6/1/2023 |
| **81443** | Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH) | 1/1/2019 |
| **81445** | Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis | 9/1/2023 |
| **81479** | Unlisted molecular pathology procedure | 3/18/2020 |
| **81507** | Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy | 1/1/2023 |
| **81518** | mRNA gene analysis of 11 genes in breast tumor tissue | 3/18/2020 |
| **81519** | mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score | 1/1/2023 |
| **81522** | mRNA, gene expression profiling by RT-PCR of 12 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk score | 10/1/2020 |

STATE OF IOWA DEPARTMENT OF
Health AND Human
SERVICES

| Code | Description | Effective Date |
|---|---|---|
| **81523** | mRNA, next-generation sequencing gene expression profiling of 70 content genes and 31 housekeeping genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk to distant metastasis | 1/1/2022 |
| **81546** | mRNA gene analysis of 10,196 genes in fine needle aspiration thyroid specimen, reported as category result (e.g., benign, suspicious) | 1/1/2021 |
| **0016U** | RNA, BCR/ABL1 major and minor breakpoint fusion transcripts, quantitative PCR amplification, blood or bone marrow, report of fusion not detected or detected with quantitation | 5/1/2022 |
| **0040U** | BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative | 1/1/2023 |
| **0069U** | (Colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score | 1/1/2023 |
| **0084U** | DNA red blood cell antigen typing | 1/1/2023 |
| **0087U** | mRNA gene expression profiling of genes in heart transplant biopsy tissue to evaluate risk of rejection | 7/1/2020 |
| **0111U** | (Colon cancer), targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis utilizing formalin-fixed paraffin-embedded tissue | 5/1/2022 |
| **0113U** | Measurement of PCA3 gene in urine and prostate-specific antigen (PSA) in serum to evaluate risk of prostate cancer | 7/1/2020 |
| **0120U** | mRNA, gene expression profiling of 58 genes in tissue sample for B-cell lymphoma classification | 7/1/2020 |
| **0157U** | APC (apc regulator of WNT signaling pathway) mrna sequence analysis (list separately in addition to code for primary procedure) | 7/1/2020 |
| **0158U** | Mlh1 (Lynch syndrome) mrna sequence analysis (list separately in addition to code for primary procedure) | 7/1/2020 |
| **0159U** | Msh2 (Lynch syndrome) mrna sequence analysis (list separately in addition to code for primary procedure) | 7/1/2020 |
| **0160U** | Msh6 (Lynch syndrome) mrna sequence analysis (list separately in addition to code for primary procedure) | 7/1/2020 |
| **0161U** | Pms2 (Lynch syndrome) mrna sequence analysis (list separately in addition to code for primary procedure) | 1/1/2023 |
| **0162U** | (Lynch syndrome), targeted mrna sequence analysis panel (mlh1, msh2, msh6, pms2) (list separately in addition to code for primary procedure) | 7/1/2020 |
| **0238U** | (Lynch syndrome), genomic DNA sequence analysis of mlh1, msh2, msh6, pms2, and epcam; including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions | 1/1/2023 |

STATE OF IOWA DEPARTMENT OF
Health AND Human
SERVICES

| Code | Description | Effective Date |
|---|---|---|
| **0252U** | Fetal aneuploidy short tandem-repeat comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploidy | 7/1/2021 |
| **S3854** | Gene expression profiling panel for use in the management of breast cancer treatment | 1/1/2017 |